Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Retesting of KCC2 cells with Ouabain - BioAssay Summary
Cation-chloride cotransporters such as K-Cl cotransport and Na-K-2Cl cotransport play major roles in a variety of physiological settings, including the modulation of GABAergic synaptic transmission. For instance, KCC2, a neuronal-specific K-Cl cotransporter is up-regulated in the brain during postnatal development, and is responsible for lowering the intracellular Cl- concentration in neurons, more .. |
_ |
Tested Compounds Tested Compounds Tested Substances Tested Substances Related BioAssays Related BioAssays |
|
|
BioActive Compounds: 1781Depositor Specified Assays | AID | Name | Type | Comment |
|---|
| 1456 | Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen | other | |
| 1799 | Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Antagonist Probe Summary | summary | |
| 1793 | Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Antagonist Ancillary Profile | other | |
Description: Vanderbilt Screening Center for GPCRs, Ion Channels and Transporters Assay Provider: Eric Delpire Assay Provider Affliation: Vanderbilt University Grant Title: Identification of Novel Modulators of Cl- dependent Transport Process via HTS Grant Number: R21NS053658-01
Cation-chloride cotransporters such as K-Cl cotransport and Na-K-2Cl cotransport play major roles in a variety of physiological settings, including the modulation of GABAergic synaptic transmission. For instance, KCC2, a neuronal-specific K-Cl cotransporter is up-regulated in the brain during postnatal development, and is responsible for lowering the intracellular Cl- concentration in neurons, thus promoting GABA inhibition. Reduction in KCC2 expression results in brain hyperexcitability, as demonstrated by animal models. Furthermore, KCC2 expression is decreased in brain tissue isolated from epileptic patients.
There are very few pharmacological agents that affect K-Cl cotransporters. First, there are no specific inhibitors of K-Cl cotransporters. Furosemide is mostly used to inhibit K-Cl cotransporter function, but the diuretic is not very potent and is not specific as it inhibits the Na-K-2Cl cotransporter (diuretic effect), many Cl- channels including the GABAA receptor. Finding new inhibitors will provide important tools for the study of KCC2 in modulating inhibitory neurotransmission. Second, there are also no compounds known to activate K-Cl cotransporter, except for N-ethylmaleimide, which affects many cellular processes as an unspecific alkylating agent. Finding a specific agent that increase KCC2 function would potentially have therapeutic value, as increased KCC2 function reduces susceptibility to epileptic seizures.
The purpose of this assay was to test compounds identified as 'hits' from the Molecular Libraries Small Molecule Repository (MLSMR) at a single concentration in the presence of ouabain against HEK cells expressing the cation-chloride cotransporter, KCC2 (same as primary screening conditions). Protocol METHOD: 1. Human embryonic kidney cells expressing KCC2 were plated at 20,000 cells/well in Dulbecco's modified medium (DMEM), 41.6% F12 (Gibco catalog 11320-033) in 384 well plate, black, clear bottom, poly-D-lysine coated (Greiner catalog 781946). 2. Cells were incubated overnight at 37 degrees C in 5%CO2. 3. Cells were loaded with 0.5 micromolar FluoZin2-AM dye (Invitrogen catalog number F24189) in assay buffer (Hanks Buffered Salt Solution, 20 mM HEPES, 0.2 mM oubain) for 48 minutes. 4. Dye was removed and the plate imaged using the Hamamatsu FDSS kinetic plate reader equipped with 480 nanometer excitation and 540 nanometer emission filters. 5. Compounds in DMSO were added to a final concentration of 10 micromolar (0.1% DMSO final concentration). 6. Thallium buffer stimulus (125 mM sodium bicarbonate, 12 mM thallium sulfate, 1 mM magnesium sulfate, 1.8 mM calcium sulfate, 5 mM glucose, 10 mM HEPES, pH 7.3.) was added and images collected at 1 Hz. 7. Assay buffer containing DMSO (0.1% final concentration) was used as the negative control and 2 mM bumetanide was used as the positive control on each plate.
DATA PROCESSING: 1. The raw fluorescence intensities were divided by the initial fluorescence, and the slope from 10 to 20 seconds after thallium addition was calculated and labeled 'Value1' for replicate 1 and 'Value2' for replicate 2. 2. Each compound well was compared with the mean + 3 standard deviations of the DMSO negative control population on a per plate basis. Compounds designated as 'Outcome' = 'Active' and 'Score' = '100' were statistical significant with greater than 99.7 % confidence than the negative control for the majority of the replicate testings. Wells that did not significantly vary in the majority of the replicates were labeled 'Outcome' = 'Inactive' and 'Score' = '0'. All other wells where multiple testings resulted in discrepant values were designated 'Outcome' = 'Inconclusive' and 'Score' = '50'.
Result Definitions | TID | Name | Description | | Histogram | Type | Unit |
|---|
| Outcome | The BioAssay activity outcome | | | Outcome | |
| Score | The BioAssay activity ranking score | |  | Integer | |
| 1 | Value1 | The raw fluorescence intensities were divided by the initial fluorescence, and the slope from 10 to 20 seconds after thallium addition was calculated and labeled 'Value1' for the first replicate. | |  | Float | |
| 2 | Value2 | The raw fluorescence intensities were divided by the initial fluorescence, and the slope from 10 to 20 seconds after thallium addition was calculated and labeled 'Value2' for the second replicate. | |  | Float | |
| 3 | Value3 | The raw fluorescence intensities were divided by the initial fluorescence, and the slope from 10 to 20 seconds after thallium addition was calculated and labeled 'Value3' for the third replicate. | |  | Float | |
| 4 | Value4 | The raw fluorescence intensities were divided by the initial fluorescence, and the slope from 10 to 20 seconds after thallium addition was calculated and labeled 'Value4' for the fourth replicate. | |  | Float | |
| 5 | Value5 | The raw fluorescence intensities were divided by the initial fluorescence, and the slope from 10 to 20 seconds after thallium addition was calculated and labeled 'Value5' for the fifth replicate. | |  | Float | |
| 6 | Value6 | The raw fluorescence intensities were divided by the initial fluorescence, and the slope from 10 to 20 seconds after thallium addition was calculated and labeled 'Value6' for the sixth replicate. | |  | Float | |
| 7 | Bumet_mean1 | Mean of the bumetanide positive control for the first replicate on a per-plate basis | |  | Float | |
| 8 | Bumet_mean2 | Mean of the bumetanide positive control for the second replicate on a per-plate basis | |  | Float | |
| 9 | Bumet_mean3 | Mean of the bumetanide positive control for the third replicate on a per-plate basis | |  | Float | |
| 10 | Bumet_mean4 | Mean of the bumetanide positive control for the fourth replicate on a per-plate basis | |  | Float | |
| 11 | Bumet_mean5 | Mean of the bumetanide positive control for the fifth replicate on a per-plate basis | |  | Float | |
| 12 | Bumet_mean6 | Mean of the bumetanide positive control for the sixth replicate on a per-plate basis | |  | Float | |
| 13 | Bumet_stddev1 | Standard deviation of the bumetanide positive control for the first replicate on a per-plate basis | |  | Float | |
| 14 | Bumet_stddev2 | Standard deviation of the bumetanide positive control for the second replicate on a per-plate basis | |  | Float | |
| 15 | Bumet_stddev3 | Standard deviation of the bumetanide positive control for the third replicate on a per-plate basis | |  | Float | |
| 16 | Bumet_stddev4 | Standard deviation of the bumetanide positive control for the fourth replicate on a per-plate basis | |  | Float | |
| 17 | Bumet_stddev5 | Standard deviation of the bumetanide positive control for the fifth replicate on a per-plate basis | |  | Float | |
| 18 | Bumet_stddev6 | Standard deviation of the bumetanide positive control for the sixth replicate on a per-plate basis | |  | Float | |
| 19 | DMSO_mean1 | Mean of the DMSO vehicle control for the first replicate on a per-plate basis | |  | Float | |
| 20 | DMSO_mean2 | Mean of the DMSO vehicle control for the second replicate on a per-plate basis | |  | Float | |
| 21 | DMSO_mean3 | Mean of the DMSO vehicle control for the third replicate on a per-plate basis | |  | Float | |
| 22 | DMSO_mean4 | Mean of the DMSO vehicle control for the fourth replicate on a per-plate basis | |  | Float | |
| 23 | DMSO_mean5 | Mean of the DMSO vehicle control for the fifth replicate on a per-plate basis | |  | Float | |
| 24 | DMSO_mean6 | Mean of the DMSO vehicle control for the sixth replicate on a per-plate basis | |  | Float | |
| 25 | DMSO_stddev1 | Standard deviation of the DMSO vehicle control for the first replicate on a per-plate basis | |  | Float | |
| 26 | DMSO_stddev2 | Standard deviation of the DMSO vehicle control for the second replicate on a per-plate basis | |  | Float | |
| 27 | DMSO_stddev3 | Standard deviation of the DMSO vehicle control for the third replicate on a per-plate basis | |  | Float | |
| 28 | DMSO_stddev4 | Standard deviation of the DMSO vehicle control for the fourth replicate on a per-plate basis | |  | Float | |
| 29 | DMSO_stddev5 | Standard deviation of the DMSO vehicle control for the fifth replicate on a per-plate basis | |  | Float | |
| 30 | DMSO_stddev6 | Standard deviation of the DMSO vehicle control for the sixth replicate on a per-plate basis | |  | Float | |
| 31 | zprime_DMSO_BUMET_1 | Z factor calculation of DMSO and bumetanide control populations for the first replicate. (http://en.wikipedia.org/wiki/Z-factor) | |  | Float | |
| 32 | zprime_DMSO_BUMET_2 | Z factor calculation of DMSO and bumetanide control populations for the second replicate. (http://en.wikipedia.org/wiki/Z-factor) | |  | Float | |
| 33 | zprime_DMSO_BUMET_3 | Z factor calculation of DMSO and bumetanide control populations for the third replicate. | |  | Float | |
| 34 | zprime_DMSO_BUMET_4 | Z factor calculation of DMSO and bumetanide control populations for the fourth replicate. | |  | Float | |
| 35 | zprime_DMSO_BUMET_5 | Z factor calculation of DMSO and bumetanide control populations for the fifth replicate. | |  | Float | |
| 36 | zprime_DMSO_BUMET_6 | Z factor calculation of DMSO and bumetanide control populations for the sixth replicate. | |  | Float | |
Additional Information Grant Number: R21NS053658-01
Data Table (Concise)
PageFrom: |